Reference number(s)
2236-H

SPECIALTY QUANTITY LIMIT PROGRAM

XELODA (capecitabine)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
Xeloda (capecitabine) 150 mg tablets	1250 mg/m2 administered orally twice daily for 2 weeks followed by a 1-week rest period given as 3-week cycles *Maximum total daily dose of 5600 mg (2 tablets of 150 mg plus 5 tablets of 500 mg orally twice daily) for body surface area ≥ 2.18 m^2	120 per 30 days*
Xeloda (capecitabine) 500 mg tablets		300 per 30 days*

*For malignant tumor of the rectum and other compendial indications as listed in Micromedex DrugDex.

III. REFERENCES

1. Xeloda [package insert]. South San Francisco, CA: Genentech, Inc.; March 2015.
2. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed August 7, 2017.